Charles Ross Carter
CFO, Principal Financial Officer, Principal Accounting Officer & SecretaryMr. Charles Ross Carter, also known as Charley, MS, MBA, serves as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer & Secretary at Ovid Therapeutics Inc. from July 6, 2026. Mr. Carter was Senior Vice President of Finance and Financial Planning of Ovid Therapeutics Inc. from September 2025 until July 6, 2026. Mr. Carter was Chief Financial Officer at CERo Therapeutics Holdings, Inc since February 14, 2024 until September 30, 2024 and served as its Treasurer until September 30, 2024 and also served as its Corporate Secretary since February 2024 until September 30, 2024. He served as Chief Financial Officer at iCAD, Inc. since August 02, 2021 until May 20, 2022 and served as its Secretary since May 04, 2021. He served as Interim Chief Financial Officer since May 04, 2021 until June 30, 2021. Mr. Carter served as Chief Financial Officer of Aeris Therapeutics, Inc since June 28, 2011. Mr. Carter was responsible for Aeris' finance and administration functions and assist with business development. Mr. Carter served as Chief Financial Officer at GI Dynamics, Inc. from December 2018 to April 2021 and served as its Treasurer and Secretary. Prior to joining GI Dynamics full time in 2019, Mr. Carter was a finance consultant with Danforth Advisors (“Danforth”) from March 2018 to September 2019 and 2012 to 2015. Mr. Carter served as the contract Chief Financial Advisor for GI Dynamics, finance executive for Marina Biotech (NASDAQ: MRNA) and Interelukin Genetics (NASDAQ: ILGN) and Head of finance for numerous private life sciences companies. He served as the Chief Financial Officer of Intelligent Medical Devices Inc. and served as its Head of Business Development. Mr. Carter has extensive business, financial and biotechnology experience to IntelligentMDx. He served as Vice President of Finance and Secretary of Adnexus Therapeutics Inc. until June 18, 2007. He served as Senior Director of Financial Planning and Analysis for Shire Pharmaceuticals Group, Plc and Transkaryotic Therapies (TKT). He joined Danforth in 2012. Prior to TKT, he served as Principal and Strategy Consulting Partner in the Business Design Innovation and Health Care groups at Mercer Management Consulting Incorporated. From 2015 to February 2018, Mr. Carter was Chief Financial Officer of The Guild for Human Services. He also served as a Senior Technician in the Kovler Viral Oncology Labs at the University of Chicago and evaluated business plans with ARCH Development Corporation. Mr. Carter received his M.B.A. and an M.S. degree in Molecular Genetics and Cellular Biology from the University of Chicago and his B.A. in Biology and Chemistry from Colgate University.
Positions
- Company NameOvid Therapeutics Inc.Stock CodeOVIDPositionCFO, Principal Financial Officer, Principal Accounting Officer & SecretaryColleagues
- JMJeremy Max LevinCo-Founder & Executive Chairman
- MAMargaret AlexanderCEO, President & Director
- JAJeffrey A. RonaAdvisor
- ZZZhong ZhongChief Scientific Officer
- BFBart FriedmanLead Independent Director
- BGBarbara G. DuncanIndependent Director
- RSRobert S. LangerChairman of the Scientific & Clinical Advisory Board
